MeVis Medical Solutions (M3V) AI Stock Analysis

• Market Cap: €44.41M
• Dividend Yield: 3.86%
• Average Volume (3M): 99.00
• Price to Earnings (P/E): 14.0
• Beta (1Y): 0.11
• Revenue Growth: -5.72%
• EPS Growth: -25.19%
• Country: DE
• Employees: 100
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.42
• Shares Outstanding: 1,820,000
• 10 Day Avg. Volume: 191
• 30 Day Avg. Volume: 99
• PEG Ratio: -0.46
• Price to Book (P/B): 2.53
• Price to Sales (P/S): 2.81
• P/FCF Ratio: 12.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: €27.00 ▲(9.76% Upside)

The score is driven primarily by strong financial quality (notably a debt-free balance sheet and historically high margins) and supportive valuation (low P/E and solid dividend yield). These positives are partially offset by weakening revenue/profit trends and bearish technicals (price below key moving averages despite oversold RSI).

Positive Factors

Debt-free balance sheet

A zero-debt, equity-stable balance sheet materially lowers financial risk and preserves strategic optionality. Over months this supports consistent R&D and product engineering investment, resilience through contract seasonality, and the ability to fund opportunistic M&A or partnerships without refinancing strain.

High gross and operating margins

Sustained high gross and operating margins reflect a software-driven, scalable model typical in image-based medical solutions. Durable margin structure enables reinvestment in product development and supports above-average returns on incremental revenue, cushioning profitability during moderate top-line softness.

Strong free cash flow linkage to earnings

Free cash flow that generally tracks reported earnings indicates real cash-generating operations and funding capacity for dividends, capex, and selective M&A. Over the medium term this underpins capital allocation flexibility and reduces reliance on external financing for growth or shareholder returns.

Negative Factors

Three-year revenue decline

A persistent multi-year top-line contraction signals structural challenges in demand, customer retention, or competitive positioning. Continued revenue declines can erode operating leverage, limit reinvestment capacity for product roadmap execution, and ultimately pressure long-term revenue growth prospects and market share.

Volatile cash flow conversion and FCF growth

Wide swings in cash conversion and episodic FCF declines reduce predictability of internal funding and complicate sustainable capital allocation. Over several months this volatility can force conservative dividend or investment decisions, raising execution risk for long-term product development and commercialization plans.

Step-down in profitability and returns since 2022

A material drop in net margin and moderated returns since 2022 points to weakening pricing power, mix shifts, or higher operating costs. Persistently lower profitability reduces reinvestment capacity, compresses returns on equity, and makes funding growth initiatives or maintaining dividend policies more challenging over the medium term.

MeVis Medical Solutions Business Overview & Revenue Model

Company Description

MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological disorders. It offers X-ray modalities, including computed tomography, digital mammography, digital tomosynthesis, magnetic resonance imaging, and digital sonography; and provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. The company also offers three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians, as well as internet-based special applications in teleradiology. In addition, its services are used for technical visualization and online training. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Deutschland AG.

How the Company Makes Money

MeVis Medical Solutions generates revenue through the sale and licensing of its proprietary software solutions to healthcare providers, hospitals, and medical research facilities. The company also offers maintenance and support services, which provide a recurring revenue stream. Additionally, MeVis partners with major medical device manufacturers to integrate its software into imaging systems, earning revenue from these strategic collaborations. The company benefits from long-term contracts and partnerships with leading healthcare organizations, ensuring a steady flow of income.

MeVis Medical Solutions Financial Statement Overview

Summary

High-quality fundamentals with a debt-free balance sheet (very low financial risk) and strong historical margins. The main drag is weakening operations: revenue has declined for three straight years and profitability has stepped down materially from 2022 highs, with cash flow conversion and free-cash-flow growth showing volatility.

Income Statement

Profitability is strong, with consistently healthy operating and net margins and very high gross margin in most years. However, the revenue trend is soft: revenue declined in each of the last three annual reports (2025: -3.454%, 2024: ~-2.1%, 2023: ~-7.6%), and earnings have come down from the 2022 peak (net margin ~41.5% in 2022 vs ~19.7% in 2025). Overall: high-margin model, but weakening top-line trajectory and reduced profitability versus prior highs.

Balance Sheet

Balance sheet quality is excellent with zero total debt and stable equity, which materially reduces financial risk and improves flexibility. Returns on equity are solid across the period (roughly ~17.8% to ~43.7%), though they have moderated from the unusually strong 2022 level. Overall: very conservative capital structure with attractive profitability on equity, with the main downside being the recent step-down in returns.

Cash Flow

Cash generation is generally good, with free cash flow closely tracking net income in most years (free cash flow to net income near ~0.90–0.99). That said, cash flow conversion versus reported earnings is inconsistent (operating cash flow to net income ranges from ~0.39 to ~1.37), and free cash flow growth has been volatile, including sharp declines in 2022 and 2024. Overall: solid cash profitability, but uneven year-to-year conversion and variability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.64M	16.06M	16.97M	17.34M	18.76M	16.21M
Gross Profit	5.93M	15.69M	16.48M	7.00M	18.02M	15.78M
EBITDA	3.49M	3.43M	4.82M	5.17M	7.97M	4.77M
Net Income	4.30M	3.17M	4.56M	4.92M	7.79M	4.55M
Balance Sheet
Total Assets	23.60M	25.89M	26.48M	28.05M	31.20M	27.53M
Cash, Cash Equivalents and Short-Term Investments	2.57M	6.52M	6.53M	7.74M	9.32M	7.62M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	5.60M	8.06M	8.66M	10.23M	13.38M	9.71M
Stockholders Equity	18.01M	17.83M	17.83M	17.83M	17.83M	17.83M
Cash Flow
Free Cash Flow	0.00	3.74M	2.84M	5.77M	4.72M	9.08M
Operating Cash Flow	0.00	3.88M	3.15M	5.85M	4.86M	9.13M
Investing Cash Flow	0.00	945.46K	906.80K	989.98K	58.66K	111.63K
Financing Cash Flow	0.00	-4.56M	-4.92M	-7.79M	-4.55M	-5.70M

MeVis Medical Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M3V, the sentiment is Negative. The current price of 24.6 is below the 20-day moving average (MA) of 25.17, below the 50-day MA of 24.92, and below the 200-day MA of 25.07, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 35.09 is Neutral, neither overbought nor oversold. The STOCH value of 15.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:M3V.

MeVis Medical Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	72 Outperform	€44.41M	14.03	24.14%	3.86%	-5.72%	-25.19%
ILM1	70 Outperform	€402.48M	18.08	4.18%	―	9.27%	65.65%
SBS	63 Neutral	€257.10M	16.31	―	2.71%	-1.64%	22.60%
COP	60 Neutral	€1.40B	75.45	2.87%	0.20%	1.16%	-43.53%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%